INVIVYD (IVVD) - Q4 2025 and Year End Summary
TIP of the SPEAR? - Is Invivyd's Long COVID Program Underappreciated?
Biotech
Initiating Coverage - BioMarin Pharmaceutical (BMRN) - FY 2025 Review
Rare Disease Specialist — Growing Into a Diversified Enzyme Therapy Powerhouse
Pfizer (PFE) – Q4 2025 Review
Too Big to Pivot? Part II
ADMA Biologics (ADMA) - Q4 2025 Review
DISCLAIMER: This note is intended for US recipients only and,
Merck and Co. (MRK) - Q4 2025 Review
Pressing Pause in 2026
Sanofi (SNY) FY 2025 Review
Boring is the new beautiful
Moderna (MRNA) - Q4 2025 Review
MRNA x Vaccine Regulation
Inocyte (INCY) - Q4 2025 Review
Wave 3 or Value Trap? Incyte After Q4
Novo Nordisk (NVO) - Q4 2025 Review
DISCLAIMER: This note is intended for US recipients only and,
Regeneron (REGN) – Q4 2025 Review
The Pipeline's Gotta Hold!